You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory glioblastoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou, Huzhou, Ningbo (Temozolomide, B7-H3 CAR-T)

Recruiting
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • Hangzhou, Zhejiang, China
  • +2 more
Dec 25, 2022

Glioblastoma Trial in Milwaukee (Gallium maltolate (500 mg), Gallium maltolate (1,000 mg), Gallium maltolate (1,500 mg))

Recruiting
  • Glioblastoma
  • Gallium maltolate (500 mg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Sep 20, 2022

Glioblastoma Multiforme Trial in Chapel Hill (CAR.B7-H3T cells infusion)

Recruiting
  • Glioblastoma Multiforme
  • CAR.B7-H3T cells infusion
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 25, 2022

Glioblastoma Multiforme, Anaplastic Astrocytoma Trial in New York (Bevacizumab)

Recruiting
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • New York, New York
    Lenox Hill Brain Tumor Center
Nov 10, 2022

Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma Trial in New York (Intra-arterial Cetuximab, Intra-arterial

Recruiting
  • Glioblastoma
  • +8 more
  • Intra-arterial Cetuximab
  • +2 more
  • New York, New York
    Lenox Hill Brain Tumor Center
Oct 17, 2022

Recurrent Glioblastoma Trial in Zhengzhou (Tislelizumab plus Bevacizumab)

Recruiting
  • Recurrent Glioblastoma
  • Tislelizumab plus Bevacizumab
  • Zhengzhou, Henan, China
    Henan Provincial People's Hospital
Sep 11, 2022

Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas Trial in Miami (SIACI of cetuximab and bevacizumab)

Not yet recruiting
  • Glioblastoma Multiforme
  • +4 more
  • SIACI of cetuximab and bevacizumab
  • Miami, Florida
    Jackson Memorial Hospital
Jul 14, 2023

Glioblastoma Multiforme, Anaplastic Astrocytoma Trial in New York (Bevacizumab and Carboplatin)

Suspended
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Bevacizumab and Carboplatin
  • New York, New York
    Lenox Hill Brain Tumor Center
Oct 27, 2021

Glioblastoma Trial in Korea, Republic of (Temozolomide+Metformin, Temozolomide+Placebo)

Completed
  • Glioblastoma
  • Ilsan, Gyeonggi-Do, Korea, Republic of
  • +11 more
Sep 8, 2021

Malignant Supratentorial Tumor, Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Houston (Lonafarnib, Temozolomide)

Active, not recruiting
  • Malignant Supratentorial Neoplasm
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2021

Refractory Glioblastoma Trial in Hangzhou (Elemene, Temozolomide)

Not yet recruiting
  • Refractory Glioblastoma
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Dec 16, 2020

Glioblastoma, Diffuse Intrinsic Pontine Glioma Trial in Japan (DSP-7888)

Completed
  • Glioblastoma
  • Diffuse Intrinsic Pontine Glioma
  • Nagoya, Aichi, Japan
  • +5 more
Apr 9, 2022

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Duarte (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory

Recruiting
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Oct 29, 2021

Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma Trial in Rochester

Active, not recruiting
  • Childhood Astrocytoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic
Sep 8, 2022

Glioma, Glioma, Malignant, Glioma, Mixed Trial in United States (NUV-422)

Terminated
  • Glioma
  • +23 more
  • Tucson, Arizona
  • +11 more
Sep 30, 2022

Recurrent/Refractory Glioblastoma Trial in Houston (crenolanib)

Completed
  • Recurrent/Refractory Glioblastoma
  • Houston, Texas
    MD Anderson Cancer Center
Jul 17, 2020

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Xunyang Changchun Shihua Hospital
Nov 20, 2021

Glioblastoma, Glioma, Gliosarcoma Trial in United States (Bevacizumab, TTFields Therapy)

Terminated
Has Results
  • Glioblastoma
  • +2 more
  • La Jolla, California
  • +10 more
May 12, 2021

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou (B7-H3 CAR-T, Temozolomide)

Unknown status
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • Hangzhou, Zhejiang, China
    the Second Affiliated Hospital of Zhejiang University School of
May 11, 2020

Glioblastoma Multiforme Trial in United States (Bevacizumab, BKM120)

Completed
Has Results
  • Glioblastoma Multiforme
  • New Haven, Connecticut
  • +7 more
Jun 8, 2020

Glioblastoma Trial in Aarau, Basel (C225-ILs-dox)

Completed
  • Glioblastoma
  • Aarau, Switzerland
  • +1 more
Dec 7, 2020

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Withdrawn
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Affiliated hospital of jiujiang university
Oct 18, 2020

Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma Trial in United States (Sacituzumab Govitecan-hziy (SG))

Completed
Has Results
  • Gastric Adenocarcinoma
  • +15 more
  • Sacituzumab Govitecan-hziy (SG)
  • Aurora, Colorado
  • +11 more
Aug 10, 2021

Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma Trial in United States (palbociclib

Terminated
Has Results
  • Childhood Choroid Plexus Tumor
  • +18 more
  • palbociclib isethionate
  • +2 more
  • Los Angeles, California
  • +10 more
Feb 10, 2021

Glioma, Glioblastoma, Glioblastoma Multiforme Trial in Houston (VAL-083, Dianhydrogalactitol)

Active, not recruiting
  • Glioma
  • +4 more
  • VAL-083, Dianhydrogalactitol
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 23, 2022